CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

This trial tests CD7-targeted CAR-T cell therapy — a type of treatment where immune cells are genetically modified to attack cancer cells bearing a protein called CD7 — for adults with relapsed or treatment-resistant T-cell leukemia or lymphoma (T-LBL/ALL). This aggressive blood cancer has poor outcomes when it returns or stops responding, and CAR-T therapy may provide a new option. **You may be eligible if...** - You are 18 to 75 years old - You have T-cell leukemia or lymphoma that has relapsed or is refractory (not responding to standard treatments) - Your cancer cells express the CD7 protein (confirmed by testing) - Your general health score (ECOG) is 0 to 2 - Your heart, liver, and kidney function are adequate **You may NOT be eligible if...** - You have significant heart disease or a recent heart attack - You have active graft-versus-host disease from a prior transplant - You have received CAR-T therapy before - You are pregnant or breastfeeding - You have active hepatitis B, hepatitis C, HIV, or CMV infection - You have an autoimmune disease requiring immune-suppressing medications Talk to your doctor to see if this trial is right for you.